[1] Ribes JA,Vanover-Sams CL,Baker DJ.Zygomycetes in human disease.Clin Microbiol Rev,2000,13(2):236-301.
[2] Chayakulkeeree M,Ghannoum MA,Perfect JR.Zygomycosis:the re-emerging fungal infection.Eur J Clin Microbiol Infect Dis,2006,25(4):215-229.
[3] Glockner A,Vehreschild JJ,Cornely OA.Zygomycosis-current epidemiological aspects.Mycoses,2007,50(Suppl 1):50-55.
[4] Roden MM,Zaoutis TE,Buchanan WL,et al.Epidemiology and outcome of zygomycosis:a review of 929 reported cases.Clin Infect Dis,2005,41(5):634-653.
[5] Sanz Alonso MA,Jarque Ramos I,Salavert Llet? M,et al.Epidemiology of invasive fungal infections due to Aspergillus spp.and Zygomycetes.Clin Microbiol Infect,2006,12(Suppl 7):2-6.
[6] Oh D,Notrica D.Primary cutaneous mucormycosis in infants and neonates:case report and review of the literature.J Pediatr Surg,2002,37(11):1607-1611.
[7] Marty FM,Cosimi LA,Baden LR.Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants.N Engl J Med,2004,350(9):950-952.
[8] Spellberg B,Edwards J Jr,Ibrahim A.Novel perspectives on mucormycosis:pathophysiology,presentation,and management.Clin Microbiol Rev,2005,18(3):556-569.
[9] Gonzalez CE,Rinaldi MG,Sugar AM.Zygomycosis.Infect Dis Clin North Am,2002,16(4):895-914.
[10] Khor BS,Lee MH,Leu HS,et al.Rhinocerebral mucormycosis in Taiwan.J Microbiol Immunol Infect,2003,36(4):266-269.
[11] Prabhu RM,Patel R.Mucormycosis and entomophthoramycosis:a review of the clinical manifestations,diagnosis and treatment.Clin Microbiol Infect,2004,10(Suppl 1):31-47.
[12] Lee FY,Mossad SB,Adal KA.Pulmonary mucormycosis:the last 30 years.Arch Intern Med,1999,159(12):1301-1309.
[13] de Oliveira-Neto MP,Da Silva M,Fialho Monteiro PC,et al.Cutaneous mucormycosis in a young,immunocompetent girl.Med Mycol,2006,44(6):567-570.
[14] Kontoyiannis DP,Lewis RE.Invasive zygomycosis:update on pathogenesis,clinical manifestations,and management.Infect Dis Clin North Am,2006,20(3):581-607.
[15] Greenberg RN,Scott LJ,Vaughn HH,et al.Zygomycosis (mucormycosis):emerging clinical importance and new treatments.Curr Opin Infect Dis,2004,17(6):517-525.
[16] Reid VJ,Solnik DL,Daskalakis T,et al.Management of bronchovascular mucormycosis in a diabetic:a surgical success.Ann Thorac Surg,2004,78(4):1449-1451.
[17] Sun QN,Fothergill AW,McCarthy DI,et al.In vitro activities of posaconazole,itraconazole,voriconazole,amphotericin B,and fluconazole against 37 clinical isolates of zygomycetes.Antimicrob Agents Chemother,2002,46(5):1581-1582.
[18] Torres-Narbona M,Guinea J,Martinez-Alarcon J,et al.In vitro activities of amphotericin B,caspofungin,itraconazole,posaconazole,and voriconazole against 45 clinical isolates of zygomycetes:comparison of CLSI M38-A,Sensititre YeastOne,and the E test.Antimicrob Agents Chemother,2007,51 (3):1126-1129.
[19] Hofman V,Castillo L,Betis F,et al.Usefulness of frozen section in rhinocerebral mucormycosis diagnosis and management.Pathology,2003,35(3):212-216.
[20] Guevara N.Roy D.Dutruc-Rosset C.et al.Mucormycosis-early diagnosis and treatment.Rev Laryngol Otol Rhinol (Bord),2004,125(2):127-131.
[21] Gleissner B,Schilling A.Anagnostopolous I.et al.Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymphoma,2004,45(7):1351-1360.
[22] Dannaoui E,Meis JF,Loebenberg D,et al.Activity of posaconazole in treatment of experimental disseminated zygomycosis.Antimicrob Agents Chemother,2003,47 (11):3647-3650.
[23] Sun QN,Najvar LK,Bocanegra R,et al.In vivo activity of posaconazole against Mucor spp.in an immunosuppressed-mouse model.Antimicrob Agents Chemother,2002,46(7):2310-2312.
[24] Tobon AM,Arango M,Fernandez D,et al.Mucormycosis (zygomycosis) in a heart-kidney transplant recipient:recovery after posaconazole therapy.Clin Infect Dis,2003,36(11):1488-1491. |
